IVERMECTIN (ivermectin) by Design Pharmaceuticals is clinical pharmacology pharmacokinetics following oral administration of ivermectin, plasma concentrations are approximately proportional to the dose. Approved for the following infections: strongyloidiasis of the intestinal tract ivermectin is indicated for the treatment of intestinal (i, onchocerciasis due to the nematode parasite onchocerca volvulus. First approved in 2024.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Pharmacokinetics Following oral administration of ivermectin, plasma concentrations are approximately proportional to the dose. In two studies, after single 12-mg doses of ivermectin in fasting healthy volunteers (representing a mean dose of 165 mcg/kg), the mean peak plasma…
Worked on IVERMECTIN at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Antiparasitic
Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
Comparison of Oral Ivermectin and Permethrin 5% Lotion in Treatment of Pediculosis Capitis
Comparative Study Between Topical Permethrin 5% and Oral Ivermectin for the Treatment of Scabies
Rosacea and Ivermectin